No Data
No Data
BofA Securities Maintains Accolade(ACCD.US) With Buy Rating, Cuts Target Price to $7
BofA Securities analyst Allen Lutz maintains $Accolade(ACCD.US)$ with a buy rating, and adjusts the target price from $16 to $7.According to TipRanks data, the analyst has a success rate of 51.4% and
A Quick Look at Today's Ratings for Accolade(ACCD.US), With a Forecast Between $7 to $9
On Jun 29, major Wall Street analysts update their ratings for $Accolade(ACCD.US)$, with price targets ranging from $7 to $9.Wells Fargo analyst Stan Berenshteyn maintains with a hold rating, and adju
Sector Update: Health Care Stocks Decline in Late Afternoon Trading
Health care stocks were retreating late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.4%. The iShares Biotechnology ETF (IBB)
Sector Update: Health Care
Health care stocks were retreating late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.4%. The iShares Biotechnology ETF (IBB)
Top Midday Decliners
Morgan Stanley halved Accolade's (ACCD) price target to $6 from $12 while keeping its equal-weight stock rating. Truist adjusted its price objective to $9 from $14 but maintained the buy rating. Late
Accolade Is Maintained at Buy by Stifel
Accolade Is Maintained at Buy by Stifel